News

Frontiers6d
Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer - Frontiers
3.1 Antibody-drug conjugates 3.1.1 Rova-T. Rova-T, the first DLL3-targeting ADC developed for extensive-stage SCLC (ES-SCLC), combines a humanized monoclonal antibody with a DNA cross-linker payload ...